EC Number   |
Protein Variants |
Reference |
|---|
    2.3.1.24 | more |
in HEK-293 cells, ectopically expressed murine CerS5 only sensitized cells to doxorubicin and vincristine |
752796 |
| 2.3.1.24 | more |
knockdown of CerS6 by siRNA. Profiles of non-hydroxylated and 2-hydroxy-ceramides in transgenic HeLa cells expressing different CerS isozymes and or different specific interfence RNAs, overview |
754361 |
| 2.3.1.24 | more |
LASS5 gene silencing by siRNAexogenously expressed LASS5 in lung epithelia is membrane-associated, triggering increased ceramide synthesis. Maximal inhibition is achieved when LASS5 is coexpressed with a plasmid encoding a neutral sphingomyelinase involved in sphingomyelin hydrolysis. Compared with control cells, cells transfected with LASS5 siRNA exhibit a 43% increase in rates of phosphatidylcholine synthesis |
-, 754360 |
| 2.3.1.24 | more |
no loss of activity is observed for the unglycosylated mutant (HA-tagged Lass6-N18Q) when compared with either the glycosylated mutant HA-tagged Lass6-N285Q or the glycosylated wild-type Lass6 |
752700 |
| 2.3.1.24 | more |
profiles of non-hydroxylated and 2-hydroxy-ceramides in transgenic HeLa cells expressing different CerS isozymes and or different specific interfence RNAs, overview |
754361 |
| 2.3.1.24 | N18Q |
site-directed mutagenesis, a glycosylation site mutant |
752700 |
| 2.3.1.24 | N285Q |
site-directed mutagenesis, a putative glycosylation site mutant |
752700 |
| 2.3.1.24 | S341A |
mutation in potential phosphorylation site, about 45% of wild-type activity, substrate tetracosanoyl-CoA |
754143 |
| 2.3.1.24 | S349A |
mutation in potential phosphorylation site, about 90% of wild-type activity, substrate tetracosanoyl-CoA |
754143 |
| 2.3.1.24 | T346A |
mutation in potential phosphorylation site, about 80% of wild-type activity, substrate tetracosanoyl-CoA |
754143 |
